ALFA Finder
Wed, 4 Nov
Lupin
Revenue up 11% to ₹7,827 Cr, but EBITA margin fell to 25.1% from 31.3%; US down 13.4% QoQ on Tolvaptan erosion; management hedged FY28 outlook.
Summary ready
Earnings calls
Lupin concalls
Every Lupin earnings call we streamed: the live audio and our summary of what management said.
Calls
Q2 FY27: key takeaways
Call page →Revenue up 11% to ₹7,827 Cr, but EBITA margin fell to 25.1% from 31.3%; US down 13.4% QoQ on Tolvaptan erosion; management hedged FY28 outlook.
Outlook
FY27 guidance: US revenue $1.1–1.2bn, EBITA margin 24–25%, R&D ~8%, ETR 27–28%; FY28 US '$1bn+' only hoped.
Earlier call summaries
All →
21:30 IST
BSE
Earnings Call
Lupin Earnings Call Transcript: Key Takeaways
Lupin reported record Q1 FY27 revenues of ₹8,277 crore with strong EBITDA margins of 30%. Growth was broad-based across US and India, though management expects near-term US moderation due to increased competition in key products.
17:09 IST
NSE
Earnings Call
Lupin Earnings Call: Key Takeaways
Lupin reported record FY26 revenues of ₹27,958 cr (up 23%) and EBITDA of ₹8,160 cr (up 55%). Management focuses on complex products and India prescription growth.
21:22 IST
NSE
Earnings Call
Lupin Earnings Call: Key Takeaways
Lupin delivered a record-breaking FY26 with 32% revenue growth and 68% EBITDA surge, driven by US generic exclusivity and robust India prescription growth.
21:43 IST
BSE
Earnings Call
Lupin Earnings Call: Key Takeaways
Lupin reported strong Q4 FY26 results with sales reaching ₹73,919 mn, up 33% YoY, driven by a 55% surge in North American markets.
Lupin Limited: key numbers
- Share price
- ₹2,023.40
- Market cap
- ₹92,529 Cr
- Revenue (annual)
- ₹27,958 Cr
- Net profit (annual)
- ₹5,333 Cr
- P/E (TTM)
- 17.8×Sector 43.8×
- Promoter holding
- 46.84%-0.01% QoQ
- FII holding
- 23.28%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.